While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Novo Nordisk reported turnover from obesity treatments soared by 57 per cent to 65.1 billion Danish kroner last year, largely ...

Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...

Donald Trump has on several occasions floated the idea of buying Greenland, the autonomous Danish territory. However, there ...

Your favorite toys and weight-loss drugs could be priced out of reach if Donald Trump is serious. Denmark’s defiant message ...

It’s a problem that has plagued European governments for decades, from the credit-crunch bank bailouts of 2008 to more recent ...

Robert F. Kennedy Jr. has criticized companies making weight-loss drugs such as Ozempic. He has blamed America’s obesity ...

President-elect Donald Trump threatened Tuesday to place new tariffs on imports from Denmark unless the country gives up control of Greenland, news that dented the stocks of some of Denmark’s ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. In a few short years, excitement about groundbreaking anti-obesity drugs made Novo Nordisk Europe’s ...